A cross-sectional study on the quality of life in HIV infected goldminers on highly active antiretroviral therapy in an industrial setting in South Africa
Master Thesis
2005
Permanent link to this Item
Authors
Journal Title
Link to Journal
Journal ISSN
Volume Title
Publisher
Publisher
University of Cape Town
Faculty
License
Series
Abstract
This study set out to document quality of life in the industrialized setting of HIV infected South African gold minders who are on highly-active anti-retroviral therapy, by administering the MOS SF-36, and to determine which categorical variables impact on QOL in this study cohort. It also intended to promote routine quality of life measurements, as an index of programme performance, and to strengthen the case for widened access to anti-retroviral treatment. A cross sectional survey of 202 outpatients was carried out at the central clinic at the health service hospital owned by Anglogold in the Northwest Province. Scores of eight scales of the MOS SF-36 measuring different aspects of quality of life were calculated. Demographic and laboratory data were collected from a separate case report form and the clinic database, as part of the categorical variables. Results showed that more than 59% of all respondents achieved scores of 100 for all subscale domains, and that the only categorical variables that showed statistically significant impact was age, with QOL scores on the physical function domains decreasing with age. This decrease in function was thought to be more attributable to age, than HIV status, stage or progression. The sample population was noted to have a high level of health care, and exhibited both the well-worker and survival cohort effect, as a result of a stringent pre-employment selection, on-going occupational fitness assessments and medical boarding in the case of sub-standard fitness.
Description
Includes bibliographical references (leaves 70-75).
Keywords
Reference:
Mngadi, K. 2005. A cross-sectional study on the quality of life in HIV infected goldminers on highly active antiretroviral therapy in an industrial setting in South Africa. University of Cape Town.